AbbVie Sues PTO to Extend Life of Venclexta Cancer Drug Patent

AbbVie Inc. sued the US Patent and Trademark Office to extend the term of a patent for its Venclexta cancer drug by more than four months, one week after settling lawsuits over two proposed copies that involved the patent.

The PTO miscalculated the patent term adjustment for US Patent No. 11,369,599—which covers a solid, easy-to-swallow tablet containing venetoclax, the active ingredient in Venclexta—shortchanging its life by 129 days, according to a complaint filed Monday in the US District Court for the Eastern District of Virginia. The patent is currently set to expire on May 23, 2032, according to Venclexta’s ...